Non‐clinical evidence for modulating synaptic CSF biomarkers by E2511, a novel small molecule TrkA biased positive allosteric modulator

Naoki Hiramatsu, Takeyasu Tomioka, Kazunari Sasaki, Satya Saxena, Kristin R Wildsmith, Pallavi Sachdev, Natasha Penner, Luigi Giorgi · 2025

Read Non‐clinical evidence for modulating synaptic CSF biomarkers by E2511, a novel small molecule TrkA biased positive allosteric modulator by Naoki Hiramatsu, Takeyasu Tomioka, Kazunari Sasaki, Satya Saxena, Kristin R Wildsmith, Pallavi Sachdev, Natasha Penner, Luigi Giorgi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712391.txt.

Description

Naoki Hiramatsu and co-authors probe how a candidate drug for Alzheimer's disease changes marker proteins in spinal fluid. The drug, E2511, boosts a growth signal that keeps a vulnerable class of brain cells alive; those cells wither early in the disease. Earlier work in healthy volunteers found marker shifts after dosing, but not how they arise.

The team dosed rats with the drug for two weeks and read gene activity in a brain region rich in the target cells. Genes tied to the target pathway and to synapses switched on more strongly. A standard Alzheimer's drug that raises a brain chemical did not cause the same shifts. The match between rat and human data supports the drug's stated way of working.

Catalog record

CREATORNaoki Hiramatsu, Takeyasu Tomioka, Kazunari Sasaki, Satya Saxena, Kristin R Wildsmith, Pallavi Sachdev, Natasha Penner, Luigi Giorgi
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712391

Browse the full library · About the Tower of Babel